Argel Aguilar Valles’ Post

Immunopeptidomics plays a crucial role in advancing innovative therapies targeting HLA-presented peptides. Are we ready to integrate Immunopeptidomics into clinical practice? Join the webinar featuring Tim Fugmann from Alithea Bio as he explores into immunopeptidomes with the timsTOF Ultra. Discover how leveraging extensive HLA databases can accelerate the drug development process significantly. #iPEP #timsTOF #StayCurious Shourjo Ghose Ph.D. Torsten Müller Dijana Vitko Link to webinar: https://lnkd.in/gz662mvE

📣 Webinar Alert : Immunopeptidomics 📅 29th October 2024, 4:00 - 5:00 pm CET Register now and listen to Tim Fugmann, Ph.D., CSO and Co-Founder of Alithea Biotechnology which supports Biopharma on the development of innovative therapies targeting HLA-presented peptides. Alithea has a significant track record in the absolute quantification of HLA peptides, off-target toxicity predictions and target discovery. Join and and discover how the timsTOF Ultra can lead to high quality immunopeptidomes from limited sample! #immunopeptidomics #immunepeptide #HLA #timsTOF #massspectrometry #Bruker

Stay tuned and join the webinar with our Chief Scientific Officer, Dr. Tim Fugamnn to get deep insights into #immunopeptidomics with Bruker Corporation and Alithea Bio.

🔬 Excited to present our latest scientific developments in Alzheimer’s disease (AD) at the #ADPD2024 Conference! 💡   “The small molecule GAL-201 belongs to a new pharmacological class of amyloid beta aggregation modulators that acts upstream of other known Aβ-targeting agents in Alzheimer’s disease,” explained Hermann Russ, M.D. Ph.D. founder, and Chief Scientific Officer of Galimedix Therapeutics, Inc. “The positive preclinical results presented at AD/PD™ 2024 demonstrate how treatment with GAL-201 has a potential neuroprotective effect and may also improve cognitive function.”   These results further support that toxic Aβ oligomers and protofibrils are a major underlying cause of this devastating disease. We look forward to advancing this promising new drug candidate in development. 💊 Read more here: https://lnkd.in/dtqgVZSN #AlzheimersDisease #GAL201 #LifeScience

INDUSTRY NEWS - CAR-T in autoimmunity My thoughts on the news 'Cartesian Therapeutics clears an autoimmune CAR-T trial, starts another Phase 2 and raises $130M' https://lnkd.in/eHtpW7T3 This is an exciting development that expands on tantalizing CAR-T data in autoimmunity first reported in lupus last year. Is autoimmunity the saving grace for the CAR-T field as multiple companies migrate from oncology? The competition will be no less fierce in autoimmunity where mAbs have made significant advances over the years and are truly off-the-shelf products, and cheaper as well. One key question concerns how many CAR-T products can the autoimmunity field accommodate, especially if they are all targeting B cell specific antigens. Perhaps the competitive landscape will be adjudicated by the relative durability of any response. Whereas the durability of mAb function is dictated by standard pharmacokinetics, the durability of CAR-T responses may be longer if they function as an immunomodulatory reset to the immune system. Time and data will tell. #Alloplex #celltherapies #CAR-T #oncologyresearch #cancerresearch

Today, we are sharing our CEOs thoughts on a recent exciting industry development

Proteins are the "workers" in the biochemistry of life and are critical to almost everything your body does, but sometimes, they can also cause or contribute to disease. RNAi therapeutics, which were pioneered by Alnylam, work by preventing the production of specific unwanted proteins. #ScienceCurious to learn more about the science of #RNAi? Read more here: https://bit.ly/3oR8r2l #RNAiTherapeutics #siRNA #GeneSilencing #science

AM-411 is Altamira Therapeutics' groundbreaking candidate for the treatment of #rheumatoidarthritis. An intraveneously administered nanoparticle based on the OligoPhore™ platform, AM-411 targets p65, one of the main transcriptional regulators of the NF-kB pathway and a key checkpoint in #RA inflammation What are the key differentiating factors of AM-411? - Reduced systemic side effects: Mediators of inflammation play many physiological roles in healthy tissues – AM-411 targets only inflamed tissues - Less likelihood of resistance: Blocking production of an NF-κB component by degrading mRNA to cause less resistance than inhibition of NF-κB Discover more as Altamira hopes to transform treatment paradigms for partients battling RA: https://bit.ly/3JjIBix #Science #RNADelivery #siRNA #mRNA #RNATherapeutics

Meet our latest addition to Ncardia’s cell portfolio! Introducing Ncyte® aCardiomyocytes, our newest cell model for cardiovascular research and toxicity studies! Improve in vitro testing of new treatments for atrial arrhythmias or cardiotoxicity assessments with this cell model: 🔶 High purity and chamber specific 🔶 Based on human biology 🔶 Suitable for drug screening Ncyte® aCardiomyocytes can be applied throughout the entire drug discovery pipeline, from extensive screening to crucial decision-making stages in hit-to-lead and lead optimization processes. Learn more here: https://lnkd.in/dyZz_TwZ #stemcell #atrial #cardiacdisease #cardiotoxicity #humanbiology #Ncardia #CardiovascularResearch

🍿 📽 In this video, we review the benefits of molecular therapies and their rise in prevalence. Discover the key role that plasmids play in the development and delivery of molecular therapeutics and the challenges presented by working with these constructs. #moleculartherapy #moleculartherapeutics #molecularmedicine #plasmiddna #plasmid #zymoresearch #zymoresearcheurope